CRISPR/Cas9-Driven Precision Oncology for Lung Cancer: Current Situation and Challenges

Wenyu He

2025

Abstract

Different types of lung cancer are treated in different ways. How to choose accurate treatment plan and reverse drug resistance after treatment will become the key to further improve the prognosis of lung cancer in time to come. CRISPR/Cas9 gene editing instrument. It capitalizes on the natural immune defense system of prokaryotes to accurately modify the target gene, compared to other, the design is simpler and lower cost, only the synthesis of a specific gRNA can target any gene sequence, a wider range of applications. This technology has displayed the great promise in the field of lung cancer study and the treatment, but it still needs to face bottlenecks such as off-target effects and delivery systems, and its actual clinical effectiveness needs to be rigorously verified by more in-depth studies and large-scale clinical trials.

Paper Citation

in Harvard Style

He W. (2025). CRISPR/Cas9-Driven Precision Oncology for Lung Cancer: Current Situation and Challenges. In Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS; ISBN 978-989-758-789-4, SciTePress, pages 368-373. DOI: 10.5220/0014493500004933

in Bibtex Style

@conference{befs25,
author={Wenyu He},
title={CRISPR/Cas9-Driven Precision Oncology for Lung Cancer: Current Situation and Challenges},
booktitle={Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS},
year={2025},
pages={368-373},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0014493500004933},
isbn={978-989-758-789-4},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS
TI - CRISPR/Cas9-Driven Precision Oncology for Lung Cancer: Current Situation and Challenges
SN - 978-989-758-789-4
AU - He W.
PY - 2025
SP - 368
EP - 373
DO - 10.5220/0014493500004933
PB - SciTePress